A drug commonly used to shrink enlarged prostate glands also increases the accuracy of the test used to detect aggressive forms of prostate cancer, Washington University researchers have found. Dr.

The Prostate Cancer Foundation (PCF) today announced a $10 million unrestricted gift from an anonymous donor to launch a TACTICAL (Therapy ACceleration To Intercept CAncer Lethality) Award, which will ...

There are different ways to manage fatigue during prostate cancer treatment, including exercise, sleep, complementary ...

Prostate cancer is one of the most frequently diagnosed cancers in men yet is often highly treatable when detected early. It originates in the prostate gland, located between the bladder and the penis ...

While many people are familiar with mammograms and smear tests, prostate screening is talked about far less.To shed light on this important subject ahead of Prostate Cancer Awareness Month in March, ...

If you have prostate cancer, your health care provider may have told you about a medicine called Nubeqa (darolutamide). The FDA approved Nubeqa in 2019. It is commonly used to treat prostate cancer ...

If you or a loved one has prostate cancer, you may be interested in learning about medicines used to treat it. One option is a medicine called Erleada (apalutamide). The FDA approved Erleada in 2018.

Scientists have identified a novel two-pronged treatment method, offering significant potential for patients battling advanced prostate cancer. Experts at The Institute of Cancer Research, London, ...

Living with prostate cancer can be very stressful. It can affect a person’s body, life plans, relationships, and emotions. Many people don’t realize that people with prostate cancer are at risk for ...

AI is changing how cancer care decisions are made, empowering patients and doctors to make more personalized choices. For ...

A glowing marker dye that sticks to prostate cancer cells could help surgeons to remove them in real-time, according to a paper published in the European Journal of Nuclear Medicine and Molecular ...

CHICAGO (Reuters) - Prostate cancer screening is not likely to benefit men over age 75 and is not recommended for them while more evidence is needed to determine whether younger men benefit from early ...